Immune checkpoint inhibitors in cervical cancer: Current status and research progress

Yunkai Xie; Weimin Kong; Xiaoling Zhao; He Zhang; Dan Luo; Shuning Chen

doi:10.3389/fonc.2022.984896

Immune checkpoint inhibitors in cervical cancer: Current status and research progress

Front Oncol. 2022 Oct 27:12:984896. doi: 10.3389/fonc.2022.984896. eCollection 2022.

Authors

Yunkai Xie¹, Weimin Kong¹, Xiaoling Zhao¹, He Zhang¹, Dan Luo¹, Shuning Chen¹

Affiliation

¹ Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China.

Abstract

Cervical cancer is the second most common gynecological malignant tumor endangering the health of women worldwide. Despite advances in the therapeutic strategies available to treat cervical cancer, the long-term prognosis of patients with recurrent and metastatic cervical cancer remains unsatisfactory. In recent years, immune checkpoint inhibitors (ICIs) have shown encouraging efficacy in the treatment of cervical cancer. ICIs have been approved for use in both first- and second-line cervical cancer therapies. This review summarizes the current knowledge of ICIs and the application of ICIs in clinical trials for the treatment of cervical cancer.

Keywords: PD- 1/L1; cervical cancer; clinical trials; immune checkpoint inhibitors; immunotherapy.

Publication types

Review